Project Grant K23HL185920
Award Date 8/15/26
Completion Date 7/31/31
Dollars Obligated $171K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43202, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Trustees of Boston University (doing business as Boston University Medical Campus) $1,303,658 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to study postpartum hypertension, its role in recurrent hypertensive disorders of pregnancy, and modifiable intermediates including blood pressure management and breastfeeding practices. The project grant R01HL183084 runs through January 31, 2031, with performance in...
- The National Institutes of Health Office of the Director awarded the Board of Regents of the University of Nebraska, acting through its University of Nebraska Medical Center division, $565,185 on August 17, 2026, for a randomized mechanistic clinical trial testing a collaborative care intervention for postpartum hypertension in Black women under the Cardiovascular Diseases Research program (CFDA 93.837). The study, titled PRIME CARE (Postpartum Remote Monitoring and Integration of Mobile...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $236,250 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, as a Project Grant (R21HL184279). The award funds secondary analysis of right heart catheterization data within the PVDOMICS cohort to phenotype right ventricular dysfunction across the pulmonary hypertension spectrum. The research will quantify right ventricular function including contractility, afterload, diastolic...
- The National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health awarded The Ohio State University $121,658 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how inflamed adipose tissue modulates vascular inflammation through adipocyte-derived extracellular vesicles. The funded research decodes the role of adipocyte-derived extracellular vesicle cargo in promoting cardiovascular disease risk in obese populations. The...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $729,984 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 22, 2026. The award funds development of a three-dimensional real-time cardiovascular magnetic resonance imaging (3D RT CMR) reconstruction framework for imaging patients with cardiac arrhythmias. The proposed unsupervised reconstruction method, called Generative Prior with Multi-Dynamic Modeling (GEMM), enables highly accelerated 3D RT...
- The National Heart, Lung, and Blood Institute awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $161,500 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support planning activities for a future multisite cluster randomized trial on hypertensive disorders of pregnancy prevention in safety-net clinics. The award funds a preparation phase to evaluate the feasibility and acceptability of implementation intervention...
- The National Heart, Lung, and Blood Institute awarded Women & Infants Hospital of Rhode Island $244,569 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a single-site randomized controlled trial piloting the feasibility and efficacy of postpartum enalapril treatment for cardiovascular protection in women with a history of preeclampsia. The trial will enroll women within the hospital's remote blood pressure management program to assess whether...
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals' Kaiser Foundation Research Institute $1,470,439 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate optimal physical activity timing and 24-hour activity composition for prevention of hypertensive disorders of pregnancy. The research addresses gaps in understanding how the timing and intensity of physical activity during pregnancy—particularly early versus...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $2,141,996 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and implement Community Vital Signs (CVS) strategies for identifying undiagnosed hypertension in Nigeria. The project adapts community-based screening interventions to increase blood pressure screening among adults over 18 years of age and connect patients to primary care for hypertension...